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accounted for using simulated unrestricted behavior to reason-
ably quantify the total effective dose received, as required by
regulation (2). Once the patient is released from restrictions, he or
she may feel compelled to compensate for lost quality time by
spending initially anunusual amount of time in close contact and
later returning to close-contact behavior as normal (10). After a 2-
day daytime restriction and an 8-day sleeping restriction for a
patient with 50% 24-hour uptake and a 15mCi dosage, exposure
rates from the thyroid using amore realistic effective half-life of 6
days are sufficient for the dose to an infant to accumulate to
>7.5mSv from unrestricted behavior. The dose from sleeping 8
hours per daywith the child after the 8-day restriction period can
by itself substantially exceed 5mSv. It is very important that the
parent not sleep or napwith the child for at least 2weeks. Even 4
weeks may be appropriate to be conservative about the dose
from this activity. Should the dosage to the patient exceed
15mCi, the circumstances become even more problematic.
We recognize that practical issues related to implementing
postiodine treatment guidelines and the ALARA principle are
substantial when small children are in the home. We also
recognize that clinically important effects of relatively low
levels of radiation exposure are controversial. However, if the
goal, as stated in the article, is to comply with NRC public/
family exposure guidelines, we believe that the task force’s
recommendations as summarized in their Table 2A of the
article do not provide adequate guidance to practicing phy-
sicians who may counsel these patients before or after I-131
treatment for hyperthyroidism.
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Response to Beasley CW, Moore WH, and Wagner LK
James C. Sisson
Dear Editor:
My co-authors and I appreciate the interest of Drs. Beasley,
Moore, and Wagner in our publication, ‘‘Radiation Safety in
the Treatment of Patients with Thyroid Diseases by Radio-
iodine 131I: Practice Recommendations of the American
Thyroid Association’’ (1). They importantly emphasize the
obligation to protect young and vulnerable children from
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radiation exposure when others receive 131I treatment for
hyperthyroidism.
In response to the assertion that we did not fully address
the in-depth counseling required for infants’ exposure, we
offer the following.
1) We agree that dosages greater than 15mCi are often
administered. In Tables 2A-1 and 2B-1, the list of dos-
ages included: 10, 15, 20, and 30mCi as examples.
2) Uptakes of 131I by hyperthyroid glands may exceed
50% of the administered activity, but how frequently
depends upon, among other variables, the geographic
region in which treatment is provided.
3) The effective half-life of 131I in hyperthyroid glands has
varied in different investigations. The reference cited by
Beasley et al. (2) recorded a mean effective half life of
6.2– 1.2 days in 18 patients. However, in our paper (1) we
reference a report on 224 patients in which the subgroups
hadmean effective half lives of 4.8–5.2days (3).Moreover,
effective half-lives of thyroidal 131I have varied when the
disease was Graves’ or toxic nodular goiter and whether
anti-thyroid drugs had been administered (4,5).
4) We agree that exposure after the restriction period
should be taken into account. See following text for
discussion of our guiding principles.
5) Whether our recommendations insufficiently address
the protection of the class of vulnerable very young
children is a matter of opinion and depends upon the
overall goals of the communication. Our report (1)
aimed to cover major concerns in radiation protection.
In Table 3, under Information gathering for radiation safety
precaution planning and the subtitle Home, there is a line:
‘‘Special Household Situations.provide appropriate
information and make an alternate arrangement’’
which is followed by ‘‘[when] Patient is responsible for
the care of an infant or young child.’’
We could not be all-inclusive in our recommendations,
but we expressed broad principles (1). Thus, on pg 338,
under Results and Discussion, the last sentence of the first para-
graph reads: ‘‘Individualization is stressed in predicting, cal-
culating, and measuring the retained activity in each patient.’’
And, at the beginning of Table 3, ‘‘It is incumbent upon the
Radiation Treatment Team and the patient to agree upon a plan
that, by environmental population assessments and by calcu-
lation, will not put others at risk of radiation exposure as
identified in the NRC regulations (in a correction Thyroid
21:689, the followingwas added) and ICRP recommendations.’’
Also, the title of Table 2 states, ‘‘Examples of Precaution Re-
quirements and Recommendations After Treatments with 131I.’’
Again, we could not be all-inclusive, but examples demonstrate
individual-specific calculations. When available, data specific to
the patient undergoing treatment should be used.
Of minor note, Beasley et al. refer to a report (6) describing
children of ages 1 and 3 years who received doses of 3.3 and
7.2mSv. Actually in that publication, 6 of 17 children under age
3 received greater than 1mSv, but the maximum was 5.8mSv.
Again, we welcome the reminder by Drs. Beasley, Moore
and Wagner that, in designing protection from hazards of
radiation, children, and especially those less than 3 years of
age, require particular attention.
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